Phase I Open-Label Dose Escalation of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs PF 06688992 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 17 Jan 2020 Status changed from active, no longer recruiting to completed.
- 20 May 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2019 Planned number of patients changed from 40 to 20.